Spero Therapeutics, Inc. Deferred Offering Costs
Spero Therapeutics, Inc. (SPRO) had Deferred Offering Costs of $0 as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2020-11-05
- 2020-09-30: Deferred Offering Costs $0.00.
- 2020-06-30: Deferred Offering Costs $0.00.
- 2020-03-31: Deferred Offering Costs $0.00.
- 2019-12-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 |
| 2019-12-31 | $0.00 10-Q · filed 2020-11-05 |
| 2018-12-31 | $316.00K 10-K · filed 2019-03-14 |
| 2018-06-30 | $493.00K 10-Q · filed 2018-08-09 |
| 2017-09-30 | $2.10M 10-Q · filed 2017-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |